Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     
  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     
  • Bitcoin GBP

    48,514.74
    -1,706.00 (-3.40%)
     
  • CMC Crypto 200

    1,261.13
    -96.88 (-7.13%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

Change in numbers of shares and votes in Saniona AB (publ)

PRESS RELEASE

August 31, 2020

During August, the registered number of shares and votes in Saniona AB (publ) (“Saniona”) has increased due to the directed share issue that was announced on August 10, 2020. As of August 31, 2020, the registered number of shares and votes in Saniona amounts to 61,043,690.


For more information, please contact
Rami Levin, President & CEO, Saniona, Mobile: +1 (781) 987 3144, Email: rami.levin@saniona.com
Anita Milland, Interim CFO & Head of IR, Saniona, Mobile +45-20163432. Email: anita.milland@saniona.com

This information is such information as Saniona AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 8 a.m. CET on August 31, 2020.

About Saniona

Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical development. Saniona intends to develop and commercialize treatments for rare disease indications such as hypothalamic obesity and Prader-Willi syndrome on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona also has out-licensing agreements with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and in Boston, US. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.

Attachment